Bayer said on Wednesday it struck a global licence agreement for an experimental oral cancer drug for targeted therapies with ...
With the popular social media app once again at risk of going dark, there are best practices pharma brands can use on other platforms.
The startup is bringing into Phase 1 testing an experimental treatment it says could be more effective than marketed ...
On Wednesday, H.C. Wainwright reaffirmed a Buy rating and a price target of $54.00 on Biohaven Pharmaceutical (TADAWUL:2070) ...
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Biohaven Pharmaceutical Holding Co (NYSE:BHVN) Ltd on Tuesday,... H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on ...
Piper Sandler analyst Allison Bratzel maintained a Buy rating on Biohaven Ltd. (BHVN – Research ... focusing on stocks such as Argenx Se, Ionis Pharmaceuticals, and Cogent Biosciences.
HC Wainwright reissued their buy rating on shares of Biohaven (NYSE:BHVN – Free Report) in a report issued on Tuesday,Benzinga reports. The firm currently has a $54.00 price target on the stock.
NEW YORK, NY / ACCESS Newswire / March 4, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Biohaven Ltd. ("Biohaven Ltd.") (NYSE:BHVN) concerning possible ...
Biohaven’s potassium channel drug has failed a late-stage study in bipolar mania, according to a statement in the company’s fourth-quarter earnings report.
Today, a brief rundown of news involving Acelyrin and Neumora Therapeutics, as well as updates from Biohaven, Lexicon Pharmaceuticals and Pliant Therapeutics you may have missed. Shares of Lexicon ...
Biohaven acquired BHV-7000 as part of a February 2022 buyout of Channel Biosciences. Image credit: Shutterstock / ma_Design. Biohaven’s pipeline drug BHV-7000 has failed to meet the primary endpoint ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback